The current scientific consensus is that PBM/LLLT may be a useful adjunctive therapy, but not yet a universally established standalone treatment.
Evidence Brief · Non-Pharmacologic Therapies
Red Light Therapy for Fibromyalgia: What the Evidence Actually Shows
Photobiomodulation is one of the most talked-about non-drug options in fibromyalgia care. Here's an honest read of what the trials support, what's still uncertain, and how clinicians can think about it.
Overall signal: promising, not yet definitiveAcross randomized trials and meta-analyses, red and near-infrared light have shown reductions in pain, better Fibromyalgia Impact Questionnaire (FIQ) scores, fewer tender points, and improvements in fatigue and stiffness with a very low rate of serious side effects. But most studies are small, protocols vary widely, and evidence quality is usually rated low to moderate. The current consensus: a useful adjunctive therapy, not yet an established standalone treatment.
The basics
What "red light therapy" actually means here
In the research literature you'll rarely see the phrase "red light therapy." It's published under photobiomodulation (PBM), low-level laser therapy (LLLT), or low-intensity light therapy. All describe the same idea: using specific wavelengths of light to influence cell behavior without heating tissue.
Two bands do the work:
- Red light (~630–700 nm) — acts more superficially, at the skin and just below.
- Near-infrared (~780–950 nm) — penetrates deeper, reaching muscle, fascia, and connective tissue.
It's delivered three main ways: locally to painful areas and tender points, through whole-body light beds or panels, or via handheld laser and LED devices.
The therapeutic window and dose matter more than the label
PBM outcomes are governed less by "red vs. infrared" branding than by delivered dose (fluence, J/cm²), irradiance (mW/cm²), wavelength, and treatment geometry. Tissue optics place an effective window roughly between 600–1100 nm, where absorption by water and hemoglobin is low enough to permit penetration. Red (~630–660 nm) is largely absorbed within millimeters; NIR (~810–850 nm) reaches deeper structures, which is why combined red + NIR systems are often preferred for the deep myofascial pain typical of fibromyalgia.
Expect a biphasic dose–response
PBM follows an Arndt–Schulz (biphasic) curve: too little energy does nothing, an optimal dose stimulates, and too much can inhibit. This is a plausible contributor to the heterogeneity across trials, and how two studies using "the same" therapy can land on opposite sides of that curve depending on device output and session length.
Mechanism
How it might work
No single mechanism is settled, but four are consistently proposed and each maps onto something we already suspect is happening in fibromyalgia.
Mitochondrial / ATP effects
PBM appears to stimulate cytochrome c oxidase in mitochondria, increasing ATP production and cellular energy. That's relevant because impaired energy metabolism and mitochondrial dysfunction have long been hypothesized in fibromyalgia.
Anti-inflammatory effects
Research suggests PBM may reduce inflammatory cytokines and oxidative stress, improve microcirculation, and modulate nitric oxide signaling. Many fibromyalgia patients show inflammatory dysregulation despite the condition traditionally being labeled "non-inflammatory."
Neuromodulation and central sensitization
Fibromyalgia is strongly tied to central sensitization, amplified pain signaling, and altered nociceptive processing. PBM may modulate peripheral nerve signaling and possibly central pain pathways; transcranial PBM is an emerging area exploring cognitive and neurologic effects.
Muscle recovery and circulation
Studies point to improved tissue oxygenation, local circulation, and muscle recovery, with reduced spasm, which may ease the stiffness and exercise intolerance many patients describe.
The photoacceptor story
The leading mechanistic model centers on cytochrome c oxidase (Complex IV) as the primary chromophore. Photon absorption is thought to dissociate inhibitory nitric oxide from the enzyme, restoring electron transport and raising ATP output, while a brief, controlled rise in reactive oxygen species triggers downstream signaling (NF-κB, growth factors). More recent work implicates light-sensitive ion channels and interfacial water changes as additional acceptors, and the mechanism here is still being actively revised.
Why the fibromyalgia fit is more than hand-waving
If you accept the bioenergetic-deficit and neuroinflammation hypotheses of fibromyalgia, a therapy proposed to raise cellular ATP and dampen inflammatory and oxidative load is at least mechanistically coherent. That coherence is a reason to investigate, not evidence of efficacy on its own. Keep the two separate when counseling patients.
The evidence
What the trials and reviews show
The most frequently cited synthesis is the 2019 meta-analysis by Yeh and colleagues in Pain Physician, pooling 9 randomized controlled trials and 325 patients. It reported significant improvements across FIQ scores, pain severity, tender points, fatigue, stiffness, anxiety, and depression, and concluded LLLT was "effective, safe, and well-tolerated" — while explicitly flagging substantial heterogeneity between studies.
Individual landmark trials point the same direction. Gür et al. (2002) reported improvements in pain, muscle spasm, morning stiffness, and tender-point counts. Armagan et al. (2006) found both short and long-term benefit. Ruaro et al. (2014) saw gains in pain, function, and overall symptom burden, and framed PBM as a useful non-pharmacologic option.
Newer reviews continue the pattern. A 2025 systematic review (17 studies, ~857 participants) found PBM beneficial across pain, sleep, physical function, and quality of life, and singled out whole-body delivery as a promising direction, while again noting protocol inconsistency and small samples. Emerging 2026 syntheses of PBM across chronic-pain conditions place fibromyalgia among the strongest responders, with consistently low adverse-event rates.
Read the effect sizes with the quality rating attached
The pooled Yeh analysis reported large standardized effect sizes — on the order of ~1.2 for pain and physical function and ~1.4–1.5 for fatigue, anxiety, and depression. Those are impressive numbers, but they come from a small set of methodologically limited trials: the authors noted low-to-moderate quality, unclear allocation concealment, and patient-only blinding in most studies, plus one per-protocol analysis with ~20% loss to follow-up.
Practical implication
Large effect sizes drawn from small, heterogeneous, unblinded-provider trials are exactly the pattern that shrinks when larger, better-controlled studies arrive. Present PBM as evidence-supported and low-risk vs. a settled, high-certainty intervention. Diagnostic populations also varied (most used ACR criteria; a few didn't specify), which complicates direct comparison.
The frontier
Whole-body photobiomodulation
The most interesting shift is away from spot-treating tender points and toward full-body light beds. The logic is that fibromyalgia is systemic — diffuse pain, autonomic dysfunction, sleep disturbance, fatigue, cognitive symptoms — so whole-body delivery may match the condition better than a handheld probe on one sore spot.
A UK NHS-based feasibility trial (Fitzmaurice et al., 2023) using a whole-body red/NIR bed reported positive changes in FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep, anxiety, depression, and cognition, with high tolerability across an 18-session, ~6-week course. Separately, a Spanish triple-blind, placebo-controlled RCT (Navarro-Ledesma et al.) using the same class of device found significant reductions in pain and improvements in quality of life, sustained at follow-up.
Don't conflate feasibility with efficacy
This distinction matters. The Fitzmaurice NHS study was a single-arm feasibility trial (21 entered, 19 completed) with no control or placebo group designed to test recruitment, acceptability, and outcome measures ahead of a definitive RCT, not to prove efficacy. The stronger causal signal comes from the placebo-controlled Navarro-Ledesma RCTs. Cite them accordingly.
Representative whole-body protocol (NovoTHOR-class bed)
| Wavelengths | Red + NIR, ~50:50 ratio |
| Fluence | ~25 J/cm² |
| Session length | Ramped: 6 → 12 → 20 min |
| Frequency | ~3× / week |
| Course | 18 sessions over ~6 weeks |
Durability and maintenance
Clinician observation from these programs suggests some patients hold gains while others gradually regress over months after the course ends, prompting the use of periodic maintenance "top-up" sessions. Durability of effect is one of the clearest open questions and should be part of the patient conversation up front.
Beyond pain
Sleep, fatigue, and "fibro fog" Emerging
Some studies and early transcranial-PBM work suggest possible benefit for cognitive performance, fatigue, mood, and sleep quality. This is compelling because sleep dysfunction sits at the center of fibromyalgia symptom amplification, and mitochondrial dysfunction and neuroinflammation may drive fatigue and cognitive fog. But the evidence here is genuinely preliminary, and larger neurologic-focused studies are still needed before drawing conclusions.
Safety
Safety profile Well-supported
Safety is one of the strongest parts of the PBM story. Across trials, serious adverse events are rare, the therapy is generally well tolerated, and no medication-like systemic toxicities have been identified. Occasional reports include transient fatigue, headache, temporary soreness, and overstimulation in sensitive patients, but the overall profile is favorable.
Sensible cautions even with a clean safety record
- Eye protection during whole-body and near-facial exposure, per device guidance.
- Photosensitizing medications (e.g., certain antibiotics, retinoids, St. John's Wort) warrant a review before starting.
- Active or suspected malignancy in the treatment field is a commonly cited relative caution pending clearer data.
- Sensitive patients may need a slower ramp and the flare-then-settle pattern some report is consistent with the biphasic dose curve.
None of these override the favorable overall profile; they're standard prudence for a low-risk modality being added to a complex regimen.
The caveats
Why the evidence isn't definitive yet
- Protocol variability. Wavelength, power, pulsing, dose, treatment time, body location, and number of sessions differ from study to study, making comparison difficult.
- Small samples. Many trials enroll 20–60 patients, run briefly, and have limited follow-up.
- Placebo challenges. Fibromyalgia trials are notoriously hard: placebo response is high, symptoms fluctuate naturally, and outcomes are largely subjective.
- No standardized guidelines. There's still no universally accepted dosing protocol, wavelength standard, treatment schedule, or maintenance strategy.
Where this fits
How to think about PBM in a real care plan
One of the most useful emerging ideas is that fibromyalgia probably isn't one condition — it likely represents multiple biologic subtypes, symptom drivers, and response phenotypes. That reframes the question from "does red light therapy work?" to "for whom, in what combination, and measured how?"
PBM may prove most valuable paired with longitudinal patient-reported outcomes, wearable and sleep data, inflammatory markers, and responder analysis that identifies who actually benefits. In complex chronic conditions, individualized response patterns and multimodal treatment stacks tend to matter more than one-size-fits-all care — which is exactly where structured, data-informed programs can turn a "promising" therapy into a measurable one for the patients it helps.
Sources
References
- Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Kuan YC. Low-Level Laser Therapy for Fibromyalgia: A Systematic Review and Meta-Analysis.
- Gür A, Karakoç M, Nas K, et al. Efficacy of low power laser therapy in fibromyalgia — clinical symptoms and quality of life.
- Armagan O, Tascioglu F, Ekim A, Oner C. Long-term efficacy of low-level laser therapy in women with fibromyalgia: a placebo-controlled study.
- Ruaro JA, Fréz AR, Ruaro MB, Nicolau RA. Low-level laser therapy to treat fibromyalgia.
- Fitzmaurice BC, Heneghan NR, Rayen ATA, Grenfell RL, Soundy AA. Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial.
- Navarro-Ledesma S, Carroll JD, González-Muñoz A, Burton P. Outcomes of whole-body photobiomodulation on pain, quality of life and psychological factors in fibromyalgia: a triple-blinded RCT with 6-month follow-up.
- Effectiveness of Photobiomodulation Therapy in the Management of Fibromyalgia Syndrome: A Systematic Review.
- Emerging 2026 systematic reviews of photobiomodulation across chronic-pain conditions (fibromyalgia among strongest responders; low adverse-event rates).
